Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
This news matters because it signals a concrete move toward bringing a novel, off-the-shelf treatment option to the European market for knee cartilage lesions, a condition affecting hundreds of thousands of patients annually. Currently, no approved off-the-shelf treatment exists in the U.S., where an estimated 470,000 cases of knee cartilage repair are performed each year. GelrinC, a cell-free hydrogel implant that is eroded and resorbed in the knee, allows surrounding cells to regenerate cartilage in a controlled and synchronous process. If successful, the European launch could pave the way for eventual U.S. market entry, addressing a significant unmet medical need.
The training program at Humanitas Research Hospital, a renowned orthopedic center, will be critical in building surgeon confidence and expertise with the GelrinC procedure. By establishing Centers of Excellence, Regentis aims to create a network of skilled physicians who can train others and share clinical outcomes, potentially accelerating adoption across Europe. The company’s focus on education underscores the importance of hands-on training for a novel medical device, as surgeons must be proficient in the implantation technique to achieve optimal patient outcomes.
For the orthopedic industry, GelrinC represents a potential shift toward cell-free, ready-to-use implants that simplify the surgical process compared to cell-based therapies that require harvesting and processing. If widely adopted, it could reduce treatment costs and expand access to cartilage repair for a broader patient population. Patients with knee cartilage lesions, often caused by injury or degenerative conditions, may benefit from a single-step procedure that avoids the need for multiple surgeries or long rehabilitation periods.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue including inflamed cartilage and bone. The company’s lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that addresses a market of approximately 470,000 cases annually in the U.S. where no off-the-shelf treatment is available.
For more information, visit the company’s newsroom at https://ibn.fm/RGNT and the full press release at https://ibn.fm/QOWWK.
